Daiichi Sankyo Co Ltd

Explore how Daiichi Sankyo’s patent‑cliff strategy, M&A moves, and value‑based pricing shape its future growth and investor appeal.

Explore how Daiichi Sankyo’s oncology and immunotherapy strategy drives 10‑year NPV of $2.5 billion, tackles TNBC patent cliffs, and targets M&A for growth.

Discover how Daiichi Sankyo’s partnership with General Proximity’s OmniTAC™ and its new STING‑based program could unlock undruggable oncology targets like KRAS and MYC, advancing colorectal cancer treatment.

Discover Daiichi Sankyo’s Q2 2026 earnings insights—financial highlights, growth drivers, pipeline focus, and strategic plans that shape investor outlook.

Daiichi Sankyo’s oncology assets, particularly Enhertu, have shown promising results in late-stage clinical trials, driving significant investor interest and a surge in the company’s share price, with market analysts projecting substantial revenue g…

Daiichi Sankyo Co., Ltd. is accelerating its expansion and research and development momentum through strategic investments in China, clinical trials, and partnerships, positioning the company for sustained growth and market leadership in the pharmac…

Daiichi Sankyo is developing groundbreaking lipid-lowering treatments, including oral triple combination tablets, to revolutionize the management of low-density lipoprotein cholesterol (LDL-C) and address the pressing issue of cardiovascular disease.

Daiichi Sankyo is poised for growth in the rapidly expanding global healthcare market, particularly in oncology therapies, driven by increasing demand and strategic collaborations.

Daiichi Sankyo has received approval in China for its androgen receptor-targeted therapy Datroway, a move expected to contribute to the company’s growth prospects in the Chinese market.

Daiichi Sankyo’s stock price has plummeted by 5.42% on the Tokyo Stock Exchange, sparking concerns that the company’s focus on traditional pharmaceuticals may be its downfall in a rapidly changing market.